AirSculpt

List prices per case around 12.7k in Q2 2026 indicate premium positioning, and the brand seeks to anchor on experience and recovery claims.

However, recent revenue per case declined slightly year over year, overall revenue fell despite stable same-center sales, and consumer demand is discretionary and sensitive to financing availability and macro conditions.

Competitive offerings (plastic surgery practices, Sono Bello, CoolSculpting, GLP‑1‑driven weight loss) limit unilateral price hikes.

Near-term mix expansion, including the alloClae partnership, could add some pricing latitude by addressing patients without sufficient donor fat, but this is nascent and subject to regulatory and clinical adoption risks. Net-net, limited sustainable pricing power is evident today.